EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieOpen Access · CC BY 4.0

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study

Helena Kwakwa, Jacqueline Bran, Julia Ruff, Salma Sharaf, Hyunuk Seung, Sunny Choe, Joel V Chua iD

Viruses · 2025

DOI: 10.3390/v17040510 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Viruses, 2025. Verfasst von Helena Kwakwa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Newlands Health, Philadelphia, PA 19114, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Coinfection, Emtricitabine, Hepatitis B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences (United States).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HIV and hepatitis B virus (HBV) coinfection has been associated with a higher risk of morbidity and mortality. HBV-active antiretroviral regimens have significantly improved the outcomes for coinfected people. Although bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is safe and efficacious for the treatment of HIV, there are few randomized studies on the treatment of HIV/HBV coinfection.

Methods

This open-label switch study enrolled adults with HIV/HBV coinfection from two clinical centers. The participants were switched from their current antiretroviral regimen (regardless of viral suppression) to BIC/FTC/TAF, taken once daily for 48 weeks. The primary endpoints were the proportion of participants with HIV RNA < 50 copies/mL and HBV DNA < 29 IU/mL at Week 24.

Results

Twenty-eight participants were enrolled, with a median age of 51 years; the majority were Black (89%) and male (86%). At baseline, 71% (20/28) and 79% (22/28) were HIV- and HBV-suppressed, respectively, and 64% (18/28) exhibited suppression for both. At week 24, 89% (25/28) and 86% (24/28) were HIV- and HBV-suppressed, respectively, and 82% (23/28) exhibited suppression for both. The most common treatment-related adverse event was nausea (2/28). None of the participants discontinued the treatment due to an adverse event. No serious adverse events or hepatitis flares were observed.

Conclusion

BIC/FTC/TAF is a safe and suitable option for the treatment of HIV/HBV-coinfected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsCoinfectionEmtricitabineHepatitis BHIV InfectionsTenofovirAdultFemaleHumansMaleMiddle AgedAdenineAlanineAntiviral AgentsHepatitis B virusHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsPiperazinesPyridonesTreatment OutcomeViral LoadAmides

Stichwörter der Autor:innen

HIVHIV-HBV coinfectionbictegravirhepatitis Btenofovir alafenamide

Substanzen

AdenineAlanineAnti-HIV AgentsAntiviral AgentsbictegravirEmtricitabineHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsPiperazinesPyridones

Autor:innen und Institutionen

  • Newlands Health, Philadelphia, PA 19114, USA.
  • Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
  • Gilead Sciences, Inc., Foster City, CA 94404, USA.

ORCID-Profile: Joel V Chua

Förderung

  • Gilead Sciences (United States)

Zitieren

APA

Kwakwa, H., Bran, J., Ruff, J., Sharaf, S., Seung, H., Choe, S., & Chua, J. V. (2025). Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study. Viruses. https://doi.org/10.3390/v17040510

Vancouver

Kwakwa H, Bran J, Ruff J, Sharaf S, Seung H, Choe S, et al. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study. Viruses. 2025. doi:10.3390/v17040510

BibTeX
@article{Kwakwa2025,
  author = {Kwakwa, Helena and Bran, Jacqueline and Ruff, Julia and Sharaf, Salma and Seung, Hyunuk and Choe, Sunny and Chua, Joel V},
  title = {Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17040510}
}
Kostenlos starten →